The Therapeutic Goods Administration (TGA) of Australia has declined the approval of Leqembi (lecanemab) as a treatment for ...

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

In October 2024, the TGA made the decision not to register lecanemab (LEQEMBI) on the Australian Register of Therapeutic Goods (ARTG) for the ...

We are very disappointed with the TGA's decision. Foremost it is sad for all patients, caregivers and healthcare professionals in Australia who will now have to wait longer for a treatment which can ...

BioArctic AB's (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia ...

The first development is the publication of a new book, Doctored, by American investigative journalist Charles Piller, which ...

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy Leqembi, saying its efficacy does not outweigh its risks. Explaining its ...

Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

February 28, 2025 Australia's ASIC wins case against Allianz ... recommendation for Eisai and Biogen's Alzheimer's drug, Leqembi, after concluding a safety review. February 28, 2025 U.S. health ...

Healthcare experts urge India to rewrite clinical trial rules to boost global market share India should take a page from the playbook of countries such as China and Australia if it wants a larger ...

Swedish biotech BioArctic [BRCTF], known for its Alzheimer’s drug Leqembi, is in talks with major pharmaceutical ... Participant of the ASX Group (Australian Securities Exchange) and SSX (Sydney Stock ...